Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Guided Therapeutics (GTHP) Preferred Shares Issued (2021)

Guided Therapeutics' Preferred Shares Issued history spans 2 years, with the latest figure at $1.3 million for Q4 2021.

On a quarterly basis, Preferred Shares Issued changed N/A to $1.3 million in Q4 2021 year-over-year; TTM through Sep 2022 was $1.3 million, a 948.8% increase, with the full-year FY2021 number at $1.4 million, changed N/A from a year prior.
Preferred Shares Issued hit $1.3 million in Q4 2021 for Guided Therapeutics, up from -$1.3 million in the prior quarter.
Over the last five years, Preferred Shares Issued for GTHP hit a ceiling of $1.8 million in Q1 2021 and a floor of -$1.3 million in Q3 2021.